These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 11503817)

  • 21. [Captopril and other angiotensin converting enzyme inhibitors in the treatment of hypertension].
    Hradec J
    Vnitr Lek; 1995 May; 41(5):336-9. PubMed ID: 7653065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Successful use of angiotensin II receptor antagonist (losartan) in a patient with scleroderma renal crisis].
    Hasegawa S; Iesato K; Tsukahara T; Yamamoto S; Kondou Y; Ogawa M; Ueda S
    Nihon Jinzo Gakkai Shi; 2000 Feb; 42(2):60-5. PubMed ID: 10771577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
    Berger AK; Duval S; Manske C; Vazquez G; Barber C; Miller L; Luepker RV
    Am Heart J; 2007 Jun; 153(6):1064-73. PubMed ID: 17540211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hyperkalemia during prolonged use of angiotensin II-converting enzyme inhibitors in end-stage renal insufficiency].
    Mooser V; Fellay G; Regamey C
    Schweiz Med Wochenschr; 1992 Dec; 122(50):1927-9. PubMed ID: 1465596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis.
    Fang W; Oreopoulos DG; Bargman JM
    Nephrol Dial Transplant; 2008 Nov; 23(11):3704-10. PubMed ID: 18567695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effects of the long-term treatment with losartan and captopril and of the abrupt cessation on circadian blood pressure profile].
    Gorbunov VM; Savina LV; Metelitsa VI; Deev AD
    Eksp Klin Farmakol; 2001; 64(2):45-50. PubMed ID: 11548448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of losartan therapy in the management of diabetic hypertension.
    Paul B; Sapra B; Maheshwari S; Goyal RK
    J Assoc Physicians India; 2000 May; 48(5):514-8. PubMed ID: 11273147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin II type 1 receptor blockers and congestive heart failure.
    Auer JW; Berent R; Eber B
    Circulation; 2001 Oct; 104(15):E82. PubMed ID: 11591633
    [No Abstract]   [Full Text] [Related]  

  • 30. [Clinical trials of ACE inhibitors and ARB for treatment of patients with hypertension, heart failure, and diabetic nephropathy in Japan--special reference to the dosage schedule and adverse effects].
    Kageyama S
    Nihon Yakurigaku Zasshi; 2008 Mar; 131(3):180-1. PubMed ID: 18421844
    [No Abstract]   [Full Text] [Related]  

  • 31. [Angiotensin-converting enzyme inhibitors and/or angiotensin II receptors antagonists in the treatment of arterial hypertension].
    Silance PG
    Rev Med Brux; 2003 Sep; 24(4):A253-6. PubMed ID: 14606289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiotensin-converting enzyme inhibitor-induced anemia and treatment for erythrocytosis in renal transplant recipients.
    Satoh S; Kaneko T; Seino K; Abe T; Omori S; Sugimura J; Fujioka T; Kubo T
    Nihon Jinzo Gakkai Shi; 1995 Jun; 37(6):343-7. PubMed ID: 7666600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED; Preddie DC
    Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A; Teo KK
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No effect of losartan on response to erythropoietin therapy in patients undergoing hemodialysis.
    Kato A; Takita T; Furuhashi M; Takahashi T; Maruyama Y; Hishida A
    Nephron; 2000 Dec; 86(4):538-9. PubMed ID: 11124620
    [No Abstract]   [Full Text] [Related]  

  • 36. Acute effect of trandolapril on serum erythropoietin in uremic and hypertensive patients.
    Akpolat T; Gumus T; Bedir A; Adam B
    J Nephrol; 1998; 11(2):94-7. PubMed ID: 9589381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anemia and angiotensin-converting enzyme inhibition in renal transplant recipients.
    Sizeland PC; Bailey RR; Lynn KL; Robson RA
    J Cardiovasc Pharmacol; 1990; 16 Suppl 7():S117-9. PubMed ID: 1708009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hospital intensive monitoring of adverse reactions of ACE inhibitors].
    Mangrella M; Motola G; Russo F; Mazzeo F; Giassa T; Falcone G; Rossi F; D'Alessio O; Rossi F
    Minerva Med; 1998 Apr; 89(4):91-7. PubMed ID: 9676174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Losartan versus ACE inhibitors in the treatment of hypertension.
    Jiang YC; Markind JE
    Ann Pharmacother; 1997 Nov; 31(11):1388-91. PubMed ID: 9391695
    [No Abstract]   [Full Text] [Related]  

  • 40. ACE inhibitors and survival of hemodialysis patients.
    Efrati S; Zaidenstein R; Dishy V; Beberashvili I; Sharist M; Averbukh Z; Golik A; Weissgarten J
    Am J Kidney Dis; 2002 Nov; 40(5):1023-9. PubMed ID: 12407648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.